Recludix Pharma

Gilead Sciences' acquisition of Leo Pharma’s signal transducer and activator of transcription 6 (STAT6) program is not just a major boost for the Danish group’s finances but also a nod to the growing

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

Since biotech valuations on public markets peaked in September 2021, the sector has had to contend with reduced financing availability and harsher conditions for deal-making. In December 2023, Scrip

Privately held Recludix Pharma debuted in 2021 with a $60m series A financing to back its theory for targeting the SH2 domain of the signal transducer and activator of transcription (STAT) protein f